Chlamydia trachomatis serovars A-L3 are the causative agents of hyperendemic blinding trachoma, a largely neglected disease of the developing world, and sexually transmitted infections (STI) that are epidemic worldwide. Chlamydial STI are risk factors for HIV and a cervical cancer co-factor. Control of these important human diseases is the long term goal of this project. Towards this end our goal is to develop a safe and efficacious live attenuated vaccine to prevent these diseases. The obligate intracellular life style, complex developmental biology, and antigenic structure of chlamydiae have severally hindered progress in vaccine development. A live-attenuated vaccine (LAV) will be beneficial in circumventing these difficulties. We have made a plasmid deficient trachoma strain and found it to be highly attenuated for the monkey eye. Ocular infection with the LAV is immunogenic and induces solid protective immunity to challenge with virulent trachoma organsims, Interestingly, LAV immunity was shown to be superior to natural infection mediated immunity. Ongoing studies are aimed at defining T cell immune correlates of solid protective immunity. These findings will guide further vaccine studies that are capable of preferentially targeting T cell protective immunity to both LAV and subunit vaccines.

Project Start
Project End
Budget Start
Budget End
Support Year
21
Fiscal Year
2013
Total Cost
$887,130
Indirect Cost
City
State
Country
Zip Code
Yang, Chunfu; Starr, Tregei; Song, Lihua et al. (2015) Chlamydial Lytic Exit from Host Cells Is Plasmid Regulated. MBio 6:e01648-15
Porcella, Stephen F; Carlson, John H; Sturdevant, Daniel E et al. (2015) Transcriptional profiling of human epithelial cells infected with plasmid-bearing and plasmid-deficient Chlamydia trachomatis. Infect Immun 83:534-43
Marsh, James W; Wee, Bryan A; Tyndall, Joel D A et al. (2015) A Chlamydia trachomatis strain with a chemically generated amino acid substitution (P370L) in the cthtrA gene shows reduced elementary body production. BMC Microbiol 15:194
Bonner, Christine; Caldwell, Harlan D; Carlson, John H et al. (2015) Chlamydia trachomatis virulence factor CT135 is stable in vivo but highly polymorphic in vitro. Pathog Dis 73:ftv043
Sturdevant, Gail L; Caldwell, Harlan D (2014) Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract. Pathog Dis 72:70-3
Kari, Laszlo; Bakios, Lauren E; Goheen, Morgan M et al. (2013) Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model. PLoS Negl Trop Dis 7:e2248
Song, Lihua; Carlson, John H; Whitmire, William M et al. (2013) Chlamydia trachomatis plasmid-encoded Pgp4 is a transcriptional regulator of virulence-associated genes. Infect Immun 81:636-44
Southern, Timothy; Bess, Leah; Harmon, Jillian et al. (2012) Fluorometric high-throughput assay for measuring chlamydial neutralizing antibody. Clin Vaccine Immunol 19:1864-9
Henning, Tara; Fakile, Yetunde; Phillips, Christi et al. (2011) Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3). J Med Primatol 40:214-23
Kari, Laszlo; Whitmire, William M; Olivares-Zavaleta, Norma et al. (2011) A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 208:2217-23

Showing the most recent 10 out of 15 publications